-
Mashup Score: 0FDA Approves Bevacizumab Biosimilar Jobevne - Oncology Nurse Advisor - 11 hour(s) ago
Jobevne, a vascular endothelial growth factor inhibitor, was approved as a biosimilar to Avastin.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet
-
Mashup Score: 0Childhood Cancer Survivors Have Higher Risk of Chronic Conditions, Early Death - Oncology Nurse Advisor - 1 day(s) ago
Childhood cancer survivors “may experience considerable accelerated aging throughout their lifespan,” the researchers wrote.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
#Childhoodcancer survivors are more likely than the general population to develop chronic health conditions and die before reaching 65 years of age. Published in @JAMAOnc and @CancerTherAdvsr. https://t.co/mnZlg0AxRG #PedOnc
-
-
Mashup Score: 0Improving Dyspnea in Advanced Lung Cancer Linked to Improved Psychological Distress - Oncology Nurse Advisor - 2 day(s) ago
A nurse-led intervention had a greater effect on dyspnea among patients with advanced lung cancer who experienced improvement in their psychological distress.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
#Dyspnea is a pervasive and distressing problem that affects more than 70% of patients at the time of advanced #lungcancer diagnosis. Published in @JPSMjournal. https://t.co/PYOX4dUKCU #lcsm
-
-
Mashup Score: 0Young Adults with High-Grade Glioma Need Life-Stage-Specific Interventions - Oncology Nurse Advisor - 4 day(s) ago
Interviews with adolescent and young adult patients with high-grade glioma revealed a need for interventions that are life-stage specific to ease disease and treatment impacts on education, career development, and relationships.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
More tailored interventions are needed to address the unique challenges facing AYAs with high-grade #glioma and provide life-stage-appropriate support. https://t.co/Axi9gQbwbe #AYACancer #AYAonc
-
-
Mashup Score: 0Secondary vs Primary Rectal Cancer Linked With Worse Survival - Oncology Nurse Advisor - 5 day(s) ago
Investigators assessed whether a reported survival disadvantage in men with secondary rectal cancer following prostate cancer radiation therapy vs primary rectal cancer is due to patient characteristics, treatment options, or tumor biology.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
Secondary #rectalcancer after #prostatecancer radiation therapy appears to have distinct clinical genomic characteristics and worse survival odds than primary rectal cancer, investigators report. From @renalandurology. https://t.co/cZ1zcR53Rx #pcsm
-
-
Mashup Score: 0Fruquintinib Improved Outcomes With Acceptable Toxicity in Pretreated mCRC - Oncology Nurse Advisor - 6 day(s) ago
Most adverse effects with fruquintinib plus BSC were low-grade and manageable, with a low rate of discontinuation, in patients with mCRC.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
Fruquintinib plus best supportive care demonstrated a favorable safety profile and significant survival benefits for patients with refractory #mCRC, establishing it as a novel and effective oral treatment option. Published in @OncJournal. https://t.co/5Gy7GCRTbR
-
-
Mashup Score: 0Cadonilimab-Lenvatinib Combo Exhibits Activity in Advanced Endometrial Cancer - Oncology Nurse Advisor - 7 day(s) ago
“Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said Chunyan Lan, MD, PhD.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
Combination treatment with lenvatinib and cadonilimab (an anti-PD-1/CTLA-4 bispecific antibody) can produce responses in patients with advanced #endometrialCancer. Presented at #SGO2025, reported in @CancerTherAdvsr. https://t.co/o6oqa6LCpX #gyncsm
-
-
Mashup Score: 0Cancer Patients Prefer Using Telemedicine for Informed Consent - Oncology Nurse Advisor - 8 day(s) ago
Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
Many cancer patients prefer using #telemedicine over in-person visits when completing the informed consent process for a #clinicaltrial. Published in @JCOOP_ASCO and @CancerTherAdvsr. https://t.co/MQQhFNenGA
-
-
Mashup Score: 0Luveltamab Tazevibulin Proves Active in FRα+ Platinum-Resistant Ovarian Cancer - Oncology Nurse Advisor - 10 day(s) ago
Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant #ovariancancer, Presented at #SGO2025, reported by @CancerTherAdvsr. https://t.co/STlEuCjjlA #gyncsm
-
-
Mashup Score: 1Prehabilitation Reduces Postoperative Complication Risk in Upper GI Cancer - Oncology Nurse Advisor - 11 day(s) ago
Prehabilitation involving a combination of exercise, nutrition, and psychological support has potential to reduce overall postoperative complications in patients undergoing surgery for upper GI cancers.
Source: www.oncologynurseadvisor.comCategories: General Medicine NewsTweet-
Postoperative complications were reduced in patients with upper #gastrointestinalCancer who participated in a prehabilitation program consisting of exercise, nutritional guidance, and psychological support. Published in @PLoSOne. https://t.co/dWcjXf0FaR #gastroCancer
-
The @FDA has approved Jobevne™ (bevacizumab-nwgd), a biosimilar to Avastin® (bevacizumab). From @eMPR. https://t.co/96cab9Hmv6 #Oncology